8-K: Karyopharm Reports 2025 Results, Eyes Key 2026 Milestones

Karyopharm Therapeutics announced its Q4 and full-year 2025 financial results, reporting $146.1 million in total revenue and providing 2026 guidance, alongside updates on pivotal myelofibrosis and endometrial cancer trials.

Summary

• Total revenue for full year 2025 was $146.1 million, an increase from $145.2 million in 2024.
• U.S. XPOVIO net product revenue for full year 2025 was $114.9 million, up from $112.8 million in 2024.
• Net loss for full year 2025 significantly widened to $196.0 million, or $17.93 per diluted share, compared to $76.4 million, or $14.00 per diluted share, in 2024.
• Loss from operations improved by 24% to $90.7 million for full year 2025, from $119.4 million in 2024.
• Cash, cash equivalents, restricted cash, and investments totaled $64.1 million as of December 31, 2025, a decrease from $109.1 million as of December 31, 2024.
• Top-line data from the Phase 3 SENTRY trial in myelofibrosis is expected in March 2026.
• Top-line data from the Phase 3 XPORT-EC-042 trial in endometrial cancer is expected in mid-2026.
• Full-year 2026 total revenue guidance is provided in the range of $130 million to $150 million.
• Full-year 2026 U.S. XPOVIO net product revenue guidance is set between $115 million and $130 million.
• R&D and selling, general and administrative (SG&A) expenses for 2026 are projected to be in the range of $230 million to $245 million.
• Existing liquidity is expected to fund current operating plans only into the second quarter of 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging financial report with a significantly widened net loss and a short cash runway, despite some operational efficiencies and upcoming clinical milestones. The revenue guidance for 2026 is also concerning.

Positives

• Full year 2025 total revenue increased to $146.1 million from $145.2 million in 2024.
• Full year 2025 U.S. XPOVIO net product revenue increased to $114.9 million from $112.8 million in 2024.
• Loss from operations improved by 24% year-over-year, from $119.4 million in 2024 to $90.7 million in 2025, reflecting improved operating efficiency and disciplined cost management.
• R&D expenses decreased to $125.6 million in 2025 from $143.2 million in 2024, due to lower personnel and stock-based compensation costs and reduced overall clinical trial spending.
• SG&A expenses decreased to $105.2 million in 2025 from $115.4 million in 2024, due to lower personnel-related costs and reduced commercial spending.
• Global patient access for selinexor expanded in 2025 with favorable reimbursement decisions in Spain and China, and regulatory approvals in over 50 countries.
• Preliminary blinded aggregate safety data from the Phase 3 SENTRY trial in myelofibrosis may suggest improvements in both hematologic and non-hematologic treatment-emergent adverse events compared to earlier data and historical ruxolitinib monotherapy.
• Enrollment in the Phase 3 SENTRY trial in myelofibrosis was completed in early September 2025.
• Enrollment in the Phase 3 XPORT-MM-031 trial in multiple myeloma was completed in the fourth quarter of 2024.

Negatives

• Net loss significantly widened to $196.0 million in 2025 from $76.4 million in 2024, primarily driven by a $62.4 million loss on extinguishment of debt and increased interest expense.
• Cash, cash equivalents, restricted cash, and investments decreased to $64.1 million as of December 31, 2025, from $109.1 million as of December 31, 2024.
• Interest expense increased to $45.8 million in 2025 from $37.4 million in 2024, reflecting higher outstanding debt and interest rates from financing transactions.
• A significant loss on extinguishment of debt of $62.4 million was recorded for the year ended December 31, 2025.
• Other (expense) income, net, shifted from $28.4 million income in 2024 to $0.2 million income for the full year 2025, primarily due to non-cash fair value remeasurements related to refinancing.
• The company expects its existing liquidity to fund operating plans only into the second quarter of 2026, indicating a short cash runway.
• The midpoint of the 2026 total revenue guidance ($140 million) is lower than the actual 2025 total revenue ($146.1 million).
• The midpoint of the 2026 U.S. XPOVIO net product revenue guidance ($122.5 million) represents only a modest increase from the 2025 actual ($114.9 million).

Risks

• There is no guarantee that Karyopharm will successfully commercialize XPOVIO or that any of its drug candidates, including selinexor, will successfully complete necessary clinical development phases or that development will continue.
• There is no guarantee that any positive developments in the development or commercialization of Karyopharm's drug candidate portfolio will result in stock price appreciation.
• Management's expectations could be affected by risks and uncertainties relating to the adoption of XPOVIO in the commercial marketplace, the timing and costs involved in commercializing XPOVIO or any approved drug candidates.
• Risks include the ability to obtain and retain regulatory approval of XPOVIO or any of Karyopharm's drug candidates, and the results of clinical and preclinical trials, including subsequent analysis of existing data and new data.
• The content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, investigational review boards, and publication review bodies, including with respect to the need for additional clinical trials, pose risks.
• The ability of Karyopharm or its third-party collaborators to fully perform their respective obligations under applicable agreements and the potential future financial implications of such agreements are risks.
• Karyopharm's ability to enroll patients in its clinical trials, unplanned cash requirements and expenditures, and the development or regulatory approval of drug candidates by competitors are significant risks.
• Substantial doubt exists regarding Karyopharm's ability to continue as a going concern.
• Risks related to Karyopharm's ability to obtain, maintain, and enforce patent and other intellectual property protection for any of its products or product candidates.

Future Outlook

Karyopharm projects total revenue for full year 2026 to be between $130 million and $150 million, with U.S. XPOVIO net product revenue expected to range from $115 million to $130 million. R&D and SG&A expenses are guided to be $230 million to $245 million. The company anticipates significant clinical milestones in 2026, including top-line data from the Phase 3 SENTRY trial in myelofibrosis in March and from the Phase 3 XPORT-EC-042 trial in endometrial cancer in mid-2026, positioning 2026 as a potential inflection point. The company expects its existing liquidity to fund current operating plans into the second quarter of 2026.

Management Comments

• "As we enter 2026, Karyopharm is approaching a defining period marked by important upcoming clinical milestones and a continued focus on disciplined execution, positioning the Company at a potential inflection point."
• "While selinexor has established a durable commercial foundation in multiple myeloma within a highly competitive treatment landscape, our late-stage programs in myelofibrosis and endometrial cancer represent an opportunity to fundamentally expand the impact and scale of our franchise."
• "If SENTRY is successful, we have the potential to meaningfully improve outcomes for patients and introduce the first-ever combination therapy in myelofibrosis, a setting with significant unmet need."
• "With the upcoming myelofibrosis readout as a key near-term catalyst and endometrial cancer representing a subsequent opportunity for further expansion, 2026 positions Karyopharm at a potential inflection point as we work to translate our science into durable patient impact and long-term value creation."

Industry Context

StockSavvy.ai notes that Karyopharm operates in highly competitive oncology markets, particularly multiple myeloma, where XPOVIO has established a commercial foundation. The company's strategic focus on late-stage programs in myelofibrosis and endometrial cancer aims to diversify its franchise and address significant unmet medical needs, potentially introducing first-in-class combination therapies. The expansion of selinexor's global access through partnerships reflects a broader industry trend of seeking international market penetration for approved therapies.

Comparison to Industry Standards

• Myelofibrosis: The Phase 3 SENTRY trial aims to introduce the first-ever combination therapy in myelofibrosis, a setting with significant unmet need where current approved therapies are primarily JAK inhibitors, such as ruxolitinib. Over 30% of patients on the most commonly prescribed JAK inhibitor often discontinue treatment due to anemia, and anemia/transfusion dependence correlates with poor prognosis. Selinexor's potential to improve outcomes in this context would be a significant advancement.
• Endometrial Cancer: The XPORT-EC-042 trial targets TP53 wild-type advanced or recurrent endometrial cancer, particularly the pMMR subgroup, where there remains an unmet need for targeted therapies. While immune checkpoint inhibitors have shown benefit, it is less pronounced in pMMR tumors compared to dMMR tumors. Selinexor as a maintenance monotherapy could address this specific gap.

Stakeholder Impact

• Shareholders: The significant net loss and short cash runway could lead to dilution from future capital raises or negatively impact the stock price. Upcoming clinical trial readouts represent potential catalysts for value creation or downside risk.
• Patients: Potential for new treatment options in myelofibrosis and endometrial cancer if clinical trials are successful, addressing significant unmet needs.
• Employees: Cost reduction initiatives mentioned for SG&A expenses could imply workforce adjustments, though not explicitly stated.
• Creditors: Increased interest expense and higher outstanding debt indicate a higher debt burden. The explicit mention of "substantial doubt exists regarding Karyopharm's ability to continue as a going concern" is highly relevant to creditors.

Next Steps

• Report top-line data from the Phase 3 SENTRY trial in myelofibrosis in March 2026.
• Report top-line data from the event-driven, Phase 3 XPORT-EC-042 trial in endometrial cancer in mid-2026.
• Report top-line data from all patients in the 60 mg cohort of the Phase 2 SENTRY-2 trial with at least 24 weeks of follow-up in the second half of 2026.
• Report top-line data from the event-driven, Phase 3 XPORT-MM-031 (EMN29) trial in the second half of 2026.
• Maintain the company's commercial foundation in the increasingly competitive multiple myeloma marketplace and drive increased XPOVIO revenues.
• Continue to support global launches by partners following regulatory and reimbursement approvals for selinexor in ex-U.S. territories.

Key Dates

Recommendation

The significant increase in net loss, substantial decrease in cash position, and a very short cash runway (into Q2 2026) raise serious concerns about the company's financial viability and necessitate a capital raise, likely dilutive. While there are important clinical milestones ahead, the current financial state and the relatively flat 2026 revenue guidance, coupled with the explicit "going concern" risk, suggest a high level of financial distress and uncertainty, making the stock a high-risk investment with a negative outlook.

Keywords

Karyopharm Therapeutics, KPTI, XPOVIO, selinexor, myelofibrosis, endometrial cancer, multiple myeloma, SENTRY trial, XPORT-EC-042 trial, financial results, 2025 results, 2026 guidance, oncology, pharmaceutical, clinical trials, revenue, net loss, cash position